T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor

NCT06478251 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Tumor, Solid

Interventions

DRUG: NW-301V
DRUG: NW-301D

Sponsor

TingBo Liang

Collaborators

[object Object]